Ionis Minority Interest vs Selling General Administrative Analysis
IONS Stock | USD 37.62 1.59 4.06% |
Ionis Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ionis Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ionis Pharmaceuticals is a good investment. Please check the relationship between Ionis Pharmaceuticals Minority Interest and its Selling General Administrative accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
Minority Interest vs Selling General Administrative
Minority Interest vs Selling General Administrative Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ionis Pharmaceuticals Minority Interest account and Selling General Administrative. At this time, the significance of the direction appears to have pay attention.
The correlation between Ionis Pharmaceuticals' Minority Interest and Selling General Administrative is -0.88. Overlapping area represents the amount of variation of Minority Interest that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Ionis Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ionis Pharmaceuticals' Minority Interest and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Minority Interest of Ionis Pharmaceuticals are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Minority Interest i.e., Ionis Pharmaceuticals' Minority Interest and Selling General Administrative go up and down completely randomly.
Correlation Coefficient | -0.88 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Minority Interest
Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Ionis Pharmaceuticals whose combined shares represent less than 50% of the total outstanding shares issued by Ionis Pharmaceuticals have a minority interest in Ionis Pharmaceuticals.Selling General Administrative
Most indicators from Ionis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 33.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.16 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 829M | 984M | 1.1B | 1.2B | Cost Of Revenue | 11M | 14M | 9.1M | 8.7M |
Ionis Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Ionis Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ionis Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.2B | 2.4B | 2.6B | 2.5B | 3.0B | 3.1B | |
Short Long Term Debt Total | 710M | 749M | 1.2B | 1.3B | 1.5B | 1.5B | |
Other Current Liab | 136.9M | (128.4M) | 127.6M | 195.5M | 217.8M | 228.7M | |
Total Current Liabilities | 273M | 290M | 241M | 312M | 448.1M | 470.5M | |
Total Stockholder Equity | 1.5B | 843M | 772M | 573M | 386.7M | 265.7M | |
Property Plant And Equipment Net | 154M | 181M | 178M | 256M | 242.9M | 255.1M | |
Net Debt | (1.8B) | (1.1B) | (954M) | (642M) | 1.1B | 1.1B | |
Retained Earnings | (707.5M) | (1.2B) | (1.2B) | (1.4B) | (1.8B) | (1.7B) | |
Cash | 2.5B | 1.9B | 2.1B | 2.0B | 399.3M | 534.5M | |
Non Current Assets Total | 512M | 260M | 267M | 331M | 348.2M | 365.6M | |
Non Currrent Assets Other | 358M | 51.1M | 60.0M | 34.6M | 62.3M | 34.5M | |
Cash And Short Term Investments | 2.5B | 1.9B | 2.1B | 2.0B | 2.3B | 2.4B | |
Common Stock Shares Outstanding | 142.9M | 139.6M | 141.0M | 141.8M | 143.2M | 83.9M | |
Liabilities And Stockholders Equity | 3.2B | 2.4B | 2.6B | 2.5B | 3.0B | 3.1B | |
Non Current Liabilities Total | 1.3B | 1.3B | 1.6B | 1.6B | 2.2B | 2.3B | |
Other Current Assets | 158M | 162M | 168M | 190M | 184.4M | 193.7M | |
Other Stockholder Equity | 2.2B | 2.1B | 2.0B | 2.1B | 2.2B | 2.3B | |
Total Liab | 1.5B | 1.5B | 1.8B | 2.0B | 2.6B | 2.7B | |
Total Current Assets | 2.7B | 2.1B | 2.3B | 2.2B | 2.6B | 2.8B | |
Short Term Debt | 2.0M | 293.2M | 3.5M | 7.5M | 53.2M | 55.8M | |
Intangible Assets | 24.0M | 25.7M | 27.9M | 29.0M | 33.4M | 24.2M | |
Accounts Payable | 16.1M | 17.2M | 11.9M | 17.9M | 26.0M | 27.3M | |
Net Receivables | 63M | 76M | 62M | 26M | 97.8M | 102.7M | |
Property Plant And Equipment Gross | 153.7M | 181.1M | 280.7M | 256M | 339.7M | 356.7M | |
Accumulated Other Comprehensive Income | (25.3M) | (21.1M) | (32.7M) | (57.5M) | (32.6M) | (31.0M) | |
Short Term Investments | 1.8B | 1.5B | 1.2B | 1.7B | 1.9B | 2.0B | |
Other Assets | 310.6M | 78.0M | 319M | 35.0M | 40.2M | 57.3M | |
Long Term Debt | 770.0M | 515.7M | 1.2B | 1.2B | 1.2B | 1.3B | |
Property Plant Equipment | 153.7M | 181.1M | 178.1M | 74.3M | 85.4M | 79.6M | |
Other Liab | 490.1M | 424M | 352M | 287.8M | 330.9M | 170.0M | |
Current Deferred Revenue | 118M | 108M | 98M | 91M | 151.1M | 158.7M | |
Inventory | 18.2M | 22.0M | 24.8M | 22.0M | 28.4M | 29.8M | |
Net Tangible Assets | 1.4B | 815.4M | 742.7M | 572.9M | 658.8M | 531.9M | |
Retained Earnings Total Equity | (707.5M) | (1.2B) | (1.2B) | (1.4B) | (1.3B) | (1.4B) | |
Long Term Debt Total | 770.0M | 515.7M | 1.2B | 1.2B | 1.4B | 1.4B | |
Capital Surpluse | 2.2B | 2.1B | 2.0B | 2.1B | 2.4B | 1.7B |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Ionis Stock analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.67) | Revenue Per Share 5.397 | Quarterly Revenue Growth (0.08) | Return On Assets (0.08) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.